Why Transurban Group is one of Australia's best blue-chip shares

Transurban Group (ASX:TCL) owns and operates a number of the country's busiest roads.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At a time where many blue chips are struggling to find and achieve growth, there is one standout in the form of Transurban Group (ASX: TCL).

Although it isn't usually regarded as one of Australia's typical blue-chips (when would you have heard it mentioned in the same sentence as, say, Commonwealth Bank of Australia (ASX: CBA), Woolworths Limited (ASX: WOW) or BHP Billiton Limited (ASX: BHP)?), Transurban is a high-quality business that has proven reliable for investors.

Indeed, its shares have risen 24.6% over the last 12 months (compared to a 5.3% decline for the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO)) and 129% over the last five years, amounting to a compound annual growth rate (CAGR) of a little over 18%.

What's more, that figure isn't even including dividends that have been distributed by the group. The chart below, provided by the company in February, shows the reliability of the group's dividend payments, which have grown at a CAGR or more than 10% since the 2009 financial year.

The company is guiding for a final dividend of 23 cents per share (partially franked), amounting to a total of 45.5 cents in financial year 2016. At today's share price, that equates to a dividend yield of 3.8%.

Source: Transurban Group investor presentation
Source: Transurban Group investor presentation

Transurban Group is the owner and operator of a number of the country's busiest roads. Amongst them are CityLink in Victoria as well as the Hills M2 Motorway and the Cross City and Lane Cove Tunnels in New South Wales. It also has controlling and non-controlling interests in numerous other roads in New South Wales, Queensland and also the United States.

Indeed, many of these assets are among Australia's most important infrastructure. Although it costs more to drive through a tollway than to go around, bypassing these roads can add precious time to a trip, so many individuals (and businesses) are willing to pay the premium.

What's more, the roads should only increase in importance as the country's population grows and as more cars take to the asphalt.

In another sign of the company's dominance, Transurban continues to grow its revenue at an even faster pace than average daily traffic numbers are growing, signifying its pricing power. Indeed, The Australian Financial Review also recently highlighted some of the deals that Transurban has in place with certain state governments that allow it to increase tolls at a faster rate than inflation. That is something that many companies can only dream of doing.

Of course, that does also introduce the risk of regulations being imposed that could hinder such agreements in the future. Meanwhile, there is also potential for regulatory authorities to block future projects or acquisitions, which would also be a negative for the business and its shareholders.

What's more, Transurban operates in a very capital intensive industry. While it may be protected from competition (i.e. how many rivals would build a freeway right next to an existing one), Transurban's various projects could be exposed to cost blowouts which would also impact the business' bottom-line results.

Finally, there is also the risk of overpaying for Transurban's shares. Following their stellar run over the last 12 months, the shares aren't necessarily cheap so investors should definitely do their own due diligence into the business before even considering a purchase.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »